Current status of newer carbapenems

Matteo Bassetti, Laura Nicolini, Silvano Esposito, Elda Righi, Claudio Viscoli

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objectives: Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. Since many bacteria have developed resistance to older agents, new beta-lactams have been introduced constantly. In the late 1970s, a new class of exceptionally broad-spectrum beta-lactams, the carbapenems, was identified. The carbapenems, such as the most popular imipenem and meropenem, have the widest spectra of antibacterial activity of all the beta-lactams and provide excellent coverage of many gram-negative and gram-positive aerobic and anaerobic bacteria. Despite the wide antibacterial spectrum, the carbapenems globally lack activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA) and Stenotrophomonas maltophilia. Methods: We reviewed the principal characteristics of the novel carbapenems and their clinical implications. Results and conclusions: We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem.

Original languageEnglish
Pages (from-to)564-575
Number of pages12
JournalCurrent Medicinal Chemistry
Volume16
Issue number5
DOIs
Publication statusPublished - 2009

Fingerprint

Carbapenems
beta-Lactams
meropenem
tomopenem
doripenem
biapenem
Bacteria
Stenotrophomonas maltophilia
Anti-Bacterial Agents
Enterococcus faecium
Aerobic Bacteria
Methicillin
Anaerobic Bacteria
Imipenem
Gram-Positive Bacteria
Methicillin-Resistant Staphylococcus aureus

Keywords

  • Biapenem
  • Carbapenems
  • Doripenem
  • Ertapenem
  • Imipenem
  • Meropenem
  • Panipenem
  • Tebipenem pivoxil

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Bassetti, M., Nicolini, L., Esposito, S., Righi, E., & Viscoli, C. (2009). Current status of newer carbapenems. Current Medicinal Chemistry, 16(5), 564-575. https://doi.org/10.2174/092986709787458498

Current status of newer carbapenems. / Bassetti, Matteo; Nicolini, Laura; Esposito, Silvano; Righi, Elda; Viscoli, Claudio.

In: Current Medicinal Chemistry, Vol. 16, No. 5, 2009, p. 564-575.

Research output: Contribution to journalArticle

Bassetti, M, Nicolini, L, Esposito, S, Righi, E & Viscoli, C 2009, 'Current status of newer carbapenems', Current Medicinal Chemistry, vol. 16, no. 5, pp. 564-575. https://doi.org/10.2174/092986709787458498
Bassetti, Matteo ; Nicolini, Laura ; Esposito, Silvano ; Righi, Elda ; Viscoli, Claudio. / Current status of newer carbapenems. In: Current Medicinal Chemistry. 2009 ; Vol. 16, No. 5. pp. 564-575.
@article{39da8aecb8c742e5b2560d453e49fd27,
title = "Current status of newer carbapenems",
abstract = "Objectives: Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. Since many bacteria have developed resistance to older agents, new beta-lactams have been introduced constantly. In the late 1970s, a new class of exceptionally broad-spectrum beta-lactams, the carbapenems, was identified. The carbapenems, such as the most popular imipenem and meropenem, have the widest spectra of antibacterial activity of all the beta-lactams and provide excellent coverage of many gram-negative and gram-positive aerobic and anaerobic bacteria. Despite the wide antibacterial spectrum, the carbapenems globally lack activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA) and Stenotrophomonas maltophilia. Methods: We reviewed the principal characteristics of the novel carbapenems and their clinical implications. Results and conclusions: We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem.",
keywords = "Biapenem, Carbapenems, Doripenem, Ertapenem, Imipenem, Meropenem, Panipenem, Tebipenem pivoxil",
author = "Matteo Bassetti and Laura Nicolini and Silvano Esposito and Elda Righi and Claudio Viscoli",
year = "2009",
doi = "10.2174/092986709787458498",
language = "English",
volume = "16",
pages = "564--575",
journal = "Current Medicinal Chemistry",
issn = "0929-8673",
publisher = "Bentham Science Publishers B.V.",
number = "5",

}

TY - JOUR

T1 - Current status of newer carbapenems

AU - Bassetti, Matteo

AU - Nicolini, Laura

AU - Esposito, Silvano

AU - Righi, Elda

AU - Viscoli, Claudio

PY - 2009

Y1 - 2009

N2 - Objectives: Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. Since many bacteria have developed resistance to older agents, new beta-lactams have been introduced constantly. In the late 1970s, a new class of exceptionally broad-spectrum beta-lactams, the carbapenems, was identified. The carbapenems, such as the most popular imipenem and meropenem, have the widest spectra of antibacterial activity of all the beta-lactams and provide excellent coverage of many gram-negative and gram-positive aerobic and anaerobic bacteria. Despite the wide antibacterial spectrum, the carbapenems globally lack activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA) and Stenotrophomonas maltophilia. Methods: We reviewed the principal characteristics of the novel carbapenems and their clinical implications. Results and conclusions: We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem.

AB - Objectives: Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. Since many bacteria have developed resistance to older agents, new beta-lactams have been introduced constantly. In the late 1970s, a new class of exceptionally broad-spectrum beta-lactams, the carbapenems, was identified. The carbapenems, such as the most popular imipenem and meropenem, have the widest spectra of antibacterial activity of all the beta-lactams and provide excellent coverage of many gram-negative and gram-positive aerobic and anaerobic bacteria. Despite the wide antibacterial spectrum, the carbapenems globally lack activity against Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA) and Stenotrophomonas maltophilia. Methods: We reviewed the principal characteristics of the novel carbapenems and their clinical implications. Results and conclusions: We included in our review: ertapenem, biapenem, panipenem, doripenem, tebipenem pivoxil and tomopenem.

KW - Biapenem

KW - Carbapenems

KW - Doripenem

KW - Ertapenem

KW - Imipenem

KW - Meropenem

KW - Panipenem

KW - Tebipenem pivoxil

UR - http://www.scopus.com/inward/record.url?scp=63149127459&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=63149127459&partnerID=8YFLogxK

U2 - 10.2174/092986709787458498

DO - 10.2174/092986709787458498

M3 - Article

VL - 16

SP - 564

EP - 575

JO - Current Medicinal Chemistry

JF - Current Medicinal Chemistry

SN - 0929-8673

IS - 5

ER -